Fractyl Health Inc. (NASDAQ:GUTS)  stock plunged on Thursday after the company hinted at a change in its U.S. regulatory strategy for Revita.Fractyl Health sotck hit its 52-week low with a session volume of 78.07 million compared to the average volume of 3.31 million, according to Benzinga Pro data.Revita is the company’s lead product candidate, designed to remodel the duodenal lining via a one-time, minimally invasive endoscopic procedure intended to restore healthy nutrient sensing and signaling disrupted ...